19964 Federal Register / Vol. 70, No.
72 / Friday, April 15, 2005 / Notices
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwrranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel Arousal and
Attention Regulation in High Risk Children.
Date: April 27, 2005.
Time: 3:30 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 5B01, Rockville,
MD 20852, (telephone conference call).
Contact Person: Marita R. Hopmann, PhD,
Scientific Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6100
Building, Room 5B01, Bethesda, MD 20892,
(301) 435–6911, hopmannm@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
98.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS).
Dated: April 8, 2005.
Anna P. Snouffler,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–7547 Filed 4–14–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: Therapeutics for the
Treatment of Retinopathy
AGENCY: National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), announces that the
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to practice the
inventions embodied in 1. E–223–1992/
0–US–01, ‘‘SIGNAL TRANSDUCTION
INHIBITOR COMPOUNDS’’, by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No. 5,359,078 (issue date
October 25, 1994); 2. E–223–1992/0–
US–02, ‘‘SIGNAL TRANSDUCTION
INHIBITOR TRIAZOLE AND DIAZOLE
VerDate jul<14>2003 14:34 Apr 14, 2005 Jkt 205001
COMPOUNDS’’ by Elise Kohn, Lance
Liotta, Christian Felder, issued Pat No.
5,482,954 (issue date January 9, 1996);
3. E–223–1992/0–US–03, ‘‘SIGNAL
TRANSDUCTION INHIBITOR 1,2,3,-
TRIAZOLO COMPOUNDS’’ by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No. 5,498,620, (issued date
March 12, 1996); 4. E–223–1992/0–US–
04, ‘‘SIGNAL TRANSDUCTION
INHIBITOR COMPOUNDS’’ by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No 5,705,514 (issued date
January 6, 1998); 5. E–223–1992/0–US–
05, ‘‘SIGNAL TRANSDUCTION
INHIBITOR COMPOUNDS’’ by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No 5,880,129 (issued date
March 9, 1999); 6. E–068–1991/1–US–
01, ‘‘METHOD FOR INHIBITING
METALLOPROTEINASE EXPRESSION’’
by Elise Kohn, Lance Liotta, issued Pat
No. Pat No. 5,602,156 (issued date
February 11, 1997); 7. E–220–1993/1–
US–01 ‘‘METHOD FOR INHIBITING
ANGIOGENESIS’’ by Elise Kohn, Lance
Liotta and Riccardo Alessandro issued
patent No 5,744,492 (issue date April
28,1998), to RFE Pharma, having a place
of business in Framingham, MA. The
patent rights in these inventions have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to
therapeutics for the treatment of
retinopathy.
DATES: Only written comments and/or
license applications which are received
by the National Institutes of Health on
or before June 14, 2005, will be
considered.
ADDRESSES: Requests for copies of the
patent and/or patent applications,
inquiries, comments and other materials
relating to the contemplated exclusive
license should be directed to: John
Stansberrry, Ph.D., Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
telephone: (301) 435–5236; Facsimile:
(301) 402–0220; e-mail:
stansbej@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
present invention provides composition
of matter claims and methods for
inhibiting angiogenesis in a host using
carboxyamido-triazole (CAI) and related
analogs. The calcium influx inhibitor
and matrix metalloproteinase
expression inhibitor, CAI, has shown
anti-cancer activity due to its ability to
influence signal transduction pathways.
CAI and CAI analogues inhibit
PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\15APN1.SGM
endothelial cell adhesion and migration
in response to basement membrane
components and thus block new vessel
formation. Pharmaceutical applications
directed to inhibiting angiogenesis offer
novel approaches to the treatment of
cancer, diabetic retinopathy,
hemangiomata, vasculidities and other
diseases associated with angiogenesis.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: April 6, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–7542 Filed 4–14–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Methods for Treating
Inflammatory Bowel Disease Using
Cholera Toxin B Subunit
AGENCY: National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
10/129,907, filed May 10, 2002 [DHHS
Ref. E–263–1999/0–US–03], entitled
‘‘Methods for treating inflammatory
bowel disease using cholera toxin B
subunit,’’ to SBL Vaccin AB, which is
located in Stockholm, Sweden. The
patent rights in these inventions have
15APN1